Want to see RDNT full AI Analyst Report?
EarningsQ2 2026 Earnings Report
RDNT Q2 2026 EPS Results
Actual EPS$0.29
Consensus EPS$0.20
Beat/MissBeat by +$0.09
One Year Ago EPS$0.31
RDNT Q2 2026 Revenue Results
Actual Revenue$622.72M
Expected Revenue$610.87M
Beat/MissBeat by +$11.85M
YoY Revenue Growth+24.99%
Earnings Announcement Details
QuarterQ2 2026
Date08/09/2026
TimeAfter Close
Conference CallSunday, August 9, 2026
RDNT Upcoming Earnings
Radnet's next earnings date is estimated for November 8, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
RDNT Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Q2 2026
Earnings Call Date:Aug 09, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call presented strong operational and financial momentum: record company revenue and adjusted EBITDA, robust advanced imaging growth and mix improvement, meaningful Digital Health ARR acceleration and commercial funnel expansion, successful acquisitions/integrations, and a major FDA clearance for breast ultrasound AI. Near-term pressures include deliberate Digital Health investment-driven margin dilution, labor cost inflation, integration/implementation expenses, and reimbursement/regulatory uncertainty. Overall, the positive operational execution, liquidity position, guidance raises for the imaging segment, and clear path to scale Digital Health ARR and profitability outweigh the transitory challenges noted.Company Guidance
Record Quarterly Revenue and Adjusted EBITDA
Total company revenue of $623.0M, up 25.0% year-over-year (from $498M), and total company adjusted EBITDA of $99.7M, up 22.7% year-over-year (from $81.2M) — both quarterly records.
Imaging Center Volume and Mix Strength
Advanced imaging drove strong volume growth: aggregate advanced imaging +21.2% YoY and same-center advanced imaging +9.6% YoY. MRI aggregate +21.0% YoY (same-center MRI +40.0%), CT aggregate +20.9% YoY (same-center CT +8.6%), PET/CT aggregate +31.0% YoY (same-center PET/CT +8.8%). Advanced imaging mix improved by 238 basis points to 29.9% of total procedural volume (from 27.5%).
Imaging Center Margin and Guidance Upside
Imaging center adjusted EBITDA margin improved by 17 basis points to 16.1% in Q2. Given the trends management raised 2026 full-year imaging center guidance: revenue to $2.37B–$2.42B, adjusted EBITDA to $345M–$358M, and free cash flow to $115M–$125M.
Strong Liquidity and Modest Leverage
Cash balance of $726M at quarter-end and net debt to adjusted EBITDA of 1.8x. Repriced debt (term loan to SOFR + 2%) and funded a $250M incremental term loan to support M&A and growth initiatives.
Digital Health Revenue and ARR Acceleration
Digital Health revenue $32.4M in Q2, up 56.5% YoY and 11.4% vs Q1. AI revenue $16.1M (+136% YoY) and enterprise imaging $16.3M (+17.3% YoY). ARR $106M, up 97% YoY and ~9% vs Q1, with management targeting >$140M ARR by year-end (implying ~91% FY growth).
Commercial Momentum and Funnel Expansion
Closed ~$21M in total contract value in Q2 (≈$37M TCV for H1). Digital Health TCV funnel expanded from ~$101M at year-start to >$224M, representing ~65M in annual contract value; nearly 3,000 customer accounts and >17M procedures through AI/informatics in the quarter (up >200% YoY).
Successful Acquisitions and Integrations
Recent Digital Health acquisitions (iCAD, C-MODE, Gleamer) contributed ~$9.3M to Q2 revenue. Gleamer integration largely complete 5 months post-close; legacy Gleamer portfolio exited Q2 at ~ $25M ARR and is on track to exceed $30M ARR by year-end. Management expects ~$4M of annual synergies by 2027 from Gleamer integration.
Regulatory Milestone — FDA Clearance for Breast Ultrasound AI
Received FDA 510(k) clearance for DeepHealth breast ultrasound AI: >98% lesion localization accuracy, +8% sensitivity for breast cancer detection, and 37% reduction in radiologist interpretation time in validation studies. Solution to be deployed across RadNet (≈1M breast ultrasound exams annually) and commercially available with potential CPT category 3 reimbursement.
Operational Productivity Initiatives
Progress on AI-powered draft reporting (ReportingPro + AI stack) with thyroid example showing >90% of autodrafts accepted without edits; expect ~15% of RadNet volumes on AI autodraft by year-end and >50% by end of Q2 2027. Pilots and rollouts underway for Diagnostic Suite, automated patient registration, and expanded TechLive remote technologist coverage.
Joint Ventures and Health System Partnerships
157 of 442 centers (~36%) are in health system partnerships. Announced a multisite JV with Saint Alphonsus (Trinity Health) in Boise (initially 5 multimodality outpatient centers) and highlighted ongoing inbound interest from health systems seeking outpatient imaging partnerships.
Revenue Cycle and DSO Strength
Continued improvements in revenue cycle with days sales outstanding at a near-company low of 31 days, supporting cash flow and growth investments.
RDNT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed